they spending way more than they will generate in revenue is the point - another iron in the fire = the fire that consumes the limited resources it has - I would have thought one of these various avenues RAP goes into would produce some decent shorter term revenue - otherwise its an R&D company and will need way more $$$ before being cashflow break even
- Forums
- ASX - By Stock
- RAP
- Ann: AstraZeneca to use new ResApp software in clinical study
Ann: AstraZeneca to use new ResApp software in clinical study, page-30
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online